In naïve mouse models18–22, the effectiveness of PD-1 blockade is observed when the treatment starts early in tumor establishment (usually within the first two weeks of tumor-exposure), possibly because this treatment timing overlaps with the effector phase of primed CTL activation2,43. This evidence concerns the gene PDCD1 and neoplasm.